Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: Placebo-controlled double-blind study of estradiol and risedronate: N01C8

Supportive Care in Cancer

Volumn 18, Issue 3, 2010, Pages 321-328

  Kearns, Ann E ^a   Northfelt, Donald W ^b   Dueck, Amylou C ^b   Atherton, Pamela J ^a   Dakhil, Shaker R ^c   Rowland Jr , Kendrith M ^d   Fuloria, Jyotsna ^e   Flynn, Patrick J ^f   Dentchev, Todor ^g   Loprinzi, Charles L ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b MAYO CLINIC   (United States)

^c WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^d Carle Cancer Center CCOP   (United States)

^e Ochsner CCOP   (United States)

^f Metro Minnesota Community Clinical Oncology Program   (United States)

^g ALTRU HEALTH SYSTEM   (United States)

Author keywords

Androgen deprivation therapy; Estradiol; Osteoporosis; Prostate cancer; Risedronate

Indexed keywords

CALCIUM; ESTRADIOL; PLACEBO; RISEDRONIC ACID; VITAMIN D;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ESTROGEN THERAPY; EXERCISE; FRACTURE; GYNECOMASTIA; HIP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSTEOLYSIS; OSTEOPOROSIS; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; ESTRADIOL; ETIDRONIC ACID; GONADOTROPIN-RELEASING HORMONE; GYNECOMASTIA; HUMANS; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS;

EID: 77949273411     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-009-0655-x     Document Type: Article

References (22)

1. SA Stoch RA Parker L Chen, et al. 2001 Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists J Clin Endocrinol Metab 86 2787 2791 10.1210/jc.86.6.2787 10.1210/jc.86.6.2787 1:CAS:528:DC%2BD3MXktlKhsr4%3D 11397888 (Pubitemid 32545740)
2. SL Greenspan P Coates SM Sereika, et al. 2005 Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer J Clin Endocrinol Metab 90 6410 6417 10.1210/jc.2005-0183 10.1210/jc.2005-0183 1:CAS:528:DC%2BD2MXhtlaltL%2FN 16189261 (Pubitemid 41759293)
3. VB Shahinian YF Kuo JL Freeman, et al. 2005 Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 154 164 10.1056/NEJMoa041943 10.1056/NEJMoa041943 1:CAS:528:DC%2BD2MXksFajuw%3D%3D 15647578 (Pubitemid 40096612)
4. MR Smith WC Lee J Brandman, et al. 2005 Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer J Clin Oncol 23 7897 7903 10.1200/JCO.2004.00.6908 10.1200/JCO.2004.00.6908 1:CAS:528:DC%2BD2MXht1Cqs7fI 16258089 (Pubitemid 46657388)
5. EP Smith J Boyd GR Frank, et al. 1994 Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man N Engl J Med 331 1056 1061 10.1056/NEJM199410203311604 10.1056/NEJM199410203311604 1:CAS:528: DyaK2MXitFWjt78%3D 8090165 (Pubitemid 24317698)
6. A Morishima MM Grumbach ER Simpson, et al. 1995 Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens J Clin Endocrinol Metab 80 3689 3698 10.1210/jc.80.12.3689 10.1210/jc.80.12.3689 1:STN:280:DyaK28%2FpsVCiug%3D%3D 8530621
7. L Gennari D Merlotti G Martini, et al. 2003 Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men J Clin Endocrinol Metab 88 5327 5333 10.1210/jc.2003-030736 10.1210/jc.2003-030736 1:CAS:528:DC%2BD3sXptVynsbo%3D 14602769 (Pubitemid 37452735)
8. S Khosla LJ Melton 3rd EJ Atkinson, et al. 2001 Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men J Clin Endocrinol Metab 86 3555 3561 10.1210/jc.86.8.3555 10.1210/jc.86.8.3555 1:CAS:528:DC%2BD3MXlvFektrg%3D 11502778 (Pubitemid 32755943)
9. P Szulc F Munoz B Claustrat, et al. 2001 Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study J Clin Endocrinol Metab 86 192 199 10.1210/jc.86.1.192 10.1210/jc.86.1.192 1:CAS:528: DC%2BD3MXhtVGnsL4%3D 11232000 (Pubitemid 32109796)
10. C Meier TV Nguyen DJ Handelsman, et al. 2008 Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study Arch Intern Med 168 47 54 10.1001/archinternmed.2007.2 10.1001/archinternmed. 2007.2 1:CAS:528:DC%2BD1cXhslSntb0%3D 18195195
11. D Mellstrom L Vandenput H Mallmin, et al. 2008 Older men with low serum estradiol and high serum SHBG have an increased risk of fractures J Bone Miner Res 23 1552 1560 10.1359/jbmr.080518 10.1359/jbmr.080518 18518773
12. A Falahati-Nini BL Riggs EJ Atkinson, et al. 2000 Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men J Clin Invest 106 1553 1560 10.1172/JCI10942 10.1172/JCI10942 1:CAS:528:DC%2BD3cXovFagur8%3D 11120762
13. MD Michaelson DS Kaufman H Lee, et al. 2007 Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer J Clin Oncol 25 1038 1042 10.1200/JCO.2006.07.3361 10.1200/JCO.2006.07.3361 1:CAS:528:DC%2BD2sXksVyrs74%3D 17369566 (Pubitemid 46596753)
14. MR Smith FJ McGovern AL Zietman, et al. 2001 Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer N Engl J Med 345 948 955 10.1056/NEJMoa010845 10.1056/NEJMoa010845 1:CAS:528:DC%2BD3MXntlehtbs%3D 11575286 (Pubitemid 34940810)
15. SL Greenspan JB Nelson DL Trump, et al. 2007 Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial Ann Intern Med 146 416 424 17371886
16. MR Smith SB Malkowicz F Chu, et al. 2008 Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study J Urol 179 152 155 10.1016/j.juro.2007.08.137 10.1016/j.juro.2007.08.137 1:STN:280: DC%2BD2sjjvVWrsw%3D%3D 18001802 (Pubitemid 350216737)
17. MR Smith MA Fallon H Lee, et al. 2004 Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial J Clin Endocrinol Metab 89 3841 3846 10.1210/jc.2003-032058 10.1210/jc.2003-032058 1:CAS:528:DC%2BD2cXmslKmtLc%3D 15292315 (Pubitemid 39071482)
18. SJ Pocock R Simon 1975 Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials Biometrics 31 103 115 10.2307/2529712 10.2307/2529712 1:STN:280:DyaE28%2FhvFeisQ%3D%3D 1100130
19. JF Hilton CR Mehta 1993 Power and sample size calculations for exact conditional tests with ordered categorical data Biometrics 49 609 616 10.2307/2532573 10.2307/2532573 1:STN:280:DyaK3sznvFSquw%3D%3D 8369392
20. SS Shapiro MB Wilk 1965 An analysis of variance test for normality Biometrika 52 591 611
21. BJ Kiralti 2001 Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer Urology 57 127 132
22. RT Chlebowski SL Hendrix RD Langer, et al. 2003 Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial JAMA 289 3243 3253 10.1001/jama.289.24.3243 10.1001/jama.289.24.3243 1:CAS:528:DC%2BD3sXkvVOktbg%3D 12824205 (Pubitemid 37430077)